<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Hydroxymethylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors (<z:chebi fb="0" ids="35664">statins</z:chebi>) have been shown to have potentially useful anticancer effects against <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> in experimental studies, but clinical studies have shown inconsistent results on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> incidence </plain></SENT>
<SENT sid="1" pm="."><plain>Most <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> are believed to develop through the <z:mpath ids='MPATH_491'>polyp</z:mpath>-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> sequence </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that <z:chebi fb="0" ids="35664">statins</z:chebi> may protect against the development of <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath>, and this may contribute to the apparent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-protective effects </plain></SENT>
<SENT sid="3" pm="."><plain>OBJECTIVE: This study aims to compare previous <z:chebi fb="0" ids="35664">statin</z:chebi> use in patients with newly diagnosed <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> against a control group without <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>METHOD: A case-control study involving 264 patients attending for diagnostic colonoscopy at the Norfolk and Norwich University Hospital was used </plain></SENT>
<SENT sid="5" pm="."><plain><z:mpath ids='MPATH_491'>Polyp</z:mpath> cases were age and sex matched against controls with <z:mpath ids='MPATH_458'>normal</z:mpath> colonoscopies </plain></SENT>
<SENT sid="6" pm="."><plain>Structured patient interviews and clinical notes were used to ascertain drug and risk factor </plain></SENT>
<SENT sid="7" pm="."><plain>Logistic regression was used to compare <z:chebi fb="0" ids="35664">statin</z:chebi> exposure and correct for confounding factors </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: There was a significant negative association between prior <z:chebi fb="0" ids="35664">statin</z:chebi> use and a diagnosis of <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> [odds ratio (OR) = 0.40 (0.24-0.76)] </plain></SENT>
<SENT sid="9" pm="."><plain>The association was significantly stronger with higher <z:chebi fb="0" ids="35664">statin</z:chebi> doses [≥40 mg <z:chebi fb="0" ids="9150">simvastatin</z:chebi> or equivalent; OR 0.33 (0.10-0.53)] or longer duration of use [&gt;5 years; OR 0.36 (0.10-0.67)] </plain></SENT>
<SENT sid="10" pm="."><plain><z:chebi fb="0" ids="35664">Statin</z:chebi> use was negatively associated with both high- and low-risk <z:mpath ids='MPATH_491'>polyps</z:mpath> </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="35664">Statins</z:chebi> may have a protective effect against the development of <z:mpath ids='MPATH_490'>adenomatous polyps</z:mpath> </plain></SENT>
<SENT sid="12" pm="."><plain>The negative association between <z:chebi fb="0" ids="35664">statin</z:chebi> use and <z:mpath ids='MPATH_491'>polyp</z:mpath> incidence showed a significant dose and duration relationship </plain></SENT>
</text></document>